Company
Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics is a leading biopharmaceutical company developing a pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
9 stories
BioXcel and Nektar expand partnership in possible treatment for pancreatic cancer
Primary objective of the study is to see if the combined drugs will be effective against pancreatic cancer
Vaxart shares sink after underwhelming results from clinical trials of its antiviral drug
The pharma company is looking on the bright side, noting that the drug has a benign safety profile
Investments and investor services
Small-Cap Snapshot: Clinical trial data results make or break biopharma companies
Deciphera Pharmaceuticals and Immunomedics shares fared well after the release of clinical trial data
Apple shares sweeter ahead of developers' conference, but Nektar Therapeutics slumps
A look at some of the movers and shakers ahead of the bell in pre-market deals
Investments and investor services
US benchmarks close higher as earnings season points to strong growth
US stocks advanced as traders remain bullish about the corporate earnings season
Nektar Therapeutics shares dive after Amikacin Inhale fails to meet primary endpoint superiority
Efficacy and safety analyses from this study will be published in due course
Nektar Therapeutics,T-Mobile US, Nova Lifestyle - PRE-MARKET
A look at what stocks are moving the needle in pre-market deals in New York